Related Experiment Videos
Fixed low-dose combination in first-line treatment of hypertension
1Section of Cardiology, Medical College of Georgia, Augusta 30912-3105, USA. mprisant@mail..mcg.edu
Insights
Low-dose fixed combination therapy, like hydrochlorothiazide and bisoprolol, significantly improves hypertension control rates. This approach enhances patient compliance and reduces side effects compared to monotherapy for managing high blood pressure.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Internal Medicine
Background:
- Hypertension control rates remain low in the USA (27%), particularly in patients with renal insufficiency and type 2 diabetes mellitus.
- Monotherapy is often insufficient for achieving target blood pressure levels (systolic blood pressure < 140 mmHg and diastolic blood pressure < 90 mmHg).
- The 6th Joint National Committee Report (JNC VI) supports the use of fixed low-dose combination drugs for initial hypertension management.
Purpose of the Study:
- To evaluate the efficacy and safety of fixed low-dose combination therapy as a first-line treatment for hypertension.
- To compare the effectiveness of hydrochlorothiazide (HCTZ) 6.25 mg combined with bisoprolol 2.5-10 mg against other antihypertensive monotherapies.
- To assess the impact of combination therapy on compliance, side effects, and overall blood pressure control.
Main Methods:
- Review of multifactorial trials examining the efficacy of hydrochlorothiazide (HCTZ) 6.25 mg in combination with bisoprolol 2.5-10 mg once daily.
- Comparison of diastolic blood pressure (DBP) control rates achieved with the combination therapy versus HCTZ 25 mg, amlodipine 2.5-10 mg, enalapril 5-40 mg, or losartan 50-100 mg.
- Assessment of the side-effect profile of the low-dose combination therapy.
Main Results:
- The fixed low-dose combination of HCTZ 6.25 mg and bisoprolol 2.5-10 mg achieved DBP control rates of 64-77%.
- This control rate was equal to or superior to high-dose monotherapies including HCTZ 25 mg, amlodipine 2.5-10 mg, enalapril 5-40 mg, and losartan 50-100 mg.
- The combination therapy demonstrated a side-effect profile similar to placebo, with uncommon occurrences of erectile dysfunction and hypokalemia.
Conclusions:
- Fixed-dose combination antihypertensive drugs offer a simplified dosing regimen, improving patient compliance and hypertension control.
- Low-dose combinations effectively manage blood pressure while decreasing dose-dependent side effects and potentially reducing overall treatment costs.
- This strategy represents a viable and effective first-line treatment option for hypertension management.
Abstract:
Hypertension is poorly controlled in most patients. The control rate, defined as a systolic blood pressure (SBP) < 140 mmHg and diastolic blood pressure (DBP) < 90 mmHg, is 27% in the USA, despite data documenting the reduction of cardiovascular events by treating diastolic hypertension and isolated systolic hypertension. Control rate is even lower for patients with renal insufficiency and type 2 diabetes mellitus. Thus, monotherapy is unlikely to achieve blood pressure control. Supported by the 6th Joint National Committee Report (JNC VI), interest has been sparked in the use of fixed low-dose combination drugs as first-line treatment of hypertension. The rationale is to enhance hypertension control by using drugs that are additive while avoiding complex regimens that result in non-compliance. When low doses of two drugs are used, adverse drug reactions are fewer compared with the maximal dose of each drug tested separately. Multifactorial trials document the efficacy of hydrochlorothiazide (HCTZ) 6.25 mg in combination with bisoprolol 2.5-10 mg once daily. DBP control rates have been 64-77% and equal to or superior to HCTZ 25 mg once daily, amlodipine 2.5-10 mg once daily, enalapril 5-40 mg once daily or losartan 50-100 mg and losartan 50 mg with 12.5 mg HCTZ once daily. This low-dose combination has a side-effect profile similar to placebo. Erectile dysfunction and hypokalaemia are uncommon. Fixed-dose combination antihypertensive drugs simplify dosing regimens, improve compliance, improve hypertension control, decrease dose-dependent side-effects, and reduce cost as the first-line treatment of hypertension.